For the third consecutive year, the Hellenic Cancer Federation (ELLOK) is convening the 3rd Synergies Forum on Cancer: Policy, Research & Funding Strategies, which will take place at the Wyndham Grand Athens from 29 June to 1 July 2026.
Bringing together more than 200 distinguished speakers from across Europe, the Forum will serve as a unique platform for dialogue among academia, policymakers, healthcare professionals, researchers, patient advocates, industry representatives, and civil society. Participation will be open to the public, reflecting ELLOK’s commitment to transparency, inclusiveness and meaningful stakeholder engagement.
Focusing on the evolving European and national cancer policy landscape, the 3rd Synergies Forum on Cancer will examine progress achieved to date, identify persistent challenges and explore innovative approaches to funding, implementation and system transformation. Particular attention will be given to translating the ambitions of the European Beating Cancer Plan and the EU Mission on Cancer into tangible improvements in prevention, early detection, diagnosis, treatment, survivorship and quality of life for people affected by cancer in Greece and across Europe.
“In a period marked by intense upheavals and complex geopolitical and social changes, Europe is being called upon to redefine its strategic priorities, while at the same time ensuring adequate space for health, the continuation of European programs, and the sustainability of healthcare and care systems,” emphasizes George Kapetanakis, President of ELLOK. “Ensuring equal access to modern therapeutic options, strengthening the role of patient organisations, enhancing health literacy, and leveraging new technologies and artificial intelligence are essential prerequisites for securing a sustainable, resilient, and patient-centred healthcare system. At ELLOK, we have a duty, both as the voice of cancer patients and as the Hellenic Cancer Mission Hub, to act as a catalyst for developments by strengthening synergies among all stakeholders through constructive and meaningful dialogue, guided by ethics, values, and a clear human-centred orientation.”
Held under the auspices of the Hellenic Ministry of Health and leading national and international organisations, the Forum continues to strengthen its role as a key meeting point for shaping the future of cancer policy and care in Greece and Europe.
ΕΛΛΗΝΙΚΟ ΚΕΙΜΕΝΟ
For the third consecutive year, the Hellenic Cancer Federation - ELLOK is organizing the highly significant cancer forum entitled «3rd Synergies Forum on Cancer: Policy, Research & Funding Strategies», which will take place at the Wyndham Grand Athensfrom June 29 to July 1, 2026. More than 200 internationally renowned speakers have been invited to participate in the conference, which will be open to the public.
Focusing on European and national cancer policies, ELLOK’s 3rd Synergies Forum on Cancer aims to highlight both the progress achieved and the challenges related to funding and reforms, while proposing meaningful solutions by encouraging constructive and productive dialogue on transforming the European vision into measurable outcomes for patients in Greece.
«Σε μια περίοδο έντονων κλυδωνισμών και σύνθετων γεωπολιτικών και κοινωνικών μεταβολών, η Ευρώπη καλείται να επανακαθορίσει τις στρατηγικές της προτεραιότητες, διασφαλίζοντας παράλληλα επαρκή χώρο, για την υγεία, τη συνέχιση των ευρωπαϊκών προγραμμάτων και τη βιωσιμότητα των συστημάτων περίθαλψης και φροντίδας», τονίζει ο Giorgos Kapetanakis, President of ELLOK. «Η εξασφάλιση της ισότιμης πρόσβασης στις σύγχρονες θεραπευτικές επιλογές, η ενδυνάμωση του ρόλου των οργανώσεων ασθενών, η ενίσχυση της εγγραματοσύνης στην υγεία, η αξιοποίηση των νέων τεχνολογιών και της τεχνητής νοημοσύνης, αποτελούν απαραίτητες προϋποθέσεις προκειμένου να διασφαλίσουμε ένα βιώσιμο, ανθεκτικό και ανθρωποκεντρικό σύστημα υγείας. Στην ΕΛΛΟΚ, έχουμε χρέος, ως η φωνή των ασθενών με καρκίνο, αλλά και ως ο Εθνικός Κόμβος για τον Καρκίνο, να λειτουργούμε ως ένας επιταχυντής των εξελίξεων, ενισχύοντας τις συνέργειες ανάμεσα σε όλους τους φορείς, μέσα από έναν γόνιμο και ουσιαστικό διάλογο, με ηθική, αξίες και σαφή ανθρωποκεντρικό προσανατολισμό».
Η διοργάνωση του 3rd Synergies Forum on Cancer πραγματοποιείται με την αιγίδα του Υπουργείου Υγείας και άλλων σημαντικών διεθνών και εγχώριων επιστημονικών φορέων. Το προσεχές χρονικό διάστημα θα αναρτηθεί αναλυτικό πρόγραμμα. Μείνετε συντονισμένοι!
Auspices
Under the Auspices of the Ministry of Health
Under the Auspices of the Ministry of Digital Governance
International Organizations
Greek Organizations
PLATINUM SPONSORS
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com.
About BRAINS Innovative Consulting Services
Brains ICS is a strategic technology and consulting company operating at the intersection of artificial intelligence, public health, and critical infrastructure transformation. The company specializes in the design, governance, and implementation of large-scale, data-driven systems that support national-level policy priorities and institutional modernization.
With a strong focus on public sector innovation, Brains ICS contributes to the transformation of healthcare systems from reactive care models to proactive, population-based health management. By leveraging advanced analytics, genomic data integration, and predictive modeling, the company supports the development of precision public health strategies aligned with European initiatives such as the European Health Data Space.
At the same time, Brains ICS plays a critical role in the digital transformation of public administrations, enabling organizations to evolve into data-driven entities through interoperable platforms, AI-powered decision-support systems, and integrated information infrastructures. The company also provides high-level Project Management Office (PMO) and governance services for complex national programs, ensuring regulatory compliance, operational coordination, and measurable impact.
In the energy sector, Brains ICS supports the transition to sustainable and efficient systems through the deployment of smart infrastructure, energy data platforms, and intelligent resource management solutions. Its work spans smart cities, energy efficiency in buildings, and advanced monitoring systems that enable real-time optimization and evidence-based policy design.
Across all domains, Brains ICS adopts a holistic approach that combines technology, strategic planning, and operational execution. The company’s mission is to act as a catalyst for systemic transformation, enabling governments and organizations to enhance resilience, efficiency, and sustainability through integrated, data-driven solutions. _
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more here
Follow us on LinkedIn
About Sandoz
Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure more than 1 billion patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products, addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006.
Sandoz Greece
Sandoz Greece operates as a subsidiary of the Sandoz Group, providing mainly generic and biosimilar medicines in the Greek market, with the goal of improving patient access to affordable and high-quality medicines.
More specifically, it provides a broad portfolio of products in key therapeutic areas such as Oncology, Immunology, Hematology, Cardiology, Endocrinology and Neurology, increasing access to essential treatments and generating savings for the healthcare system and patients.
The Greek team consists of over 85 employees who, guided by a shared culture based on integrity and inclusion, are dedicated to working collaboratively and creating a positive impact on the local community.
For more information, please visit www.sandoz.com/gr-el
GOLDEN SPONSORS
SILVER SPONSORS
OFFICIAL MEDIA PARTNERS
MEDIA SPONSORS
AUDIOVISUAL SPONSOR